The development of vaccines against influenza is crucial due to the potential for widespread outbreaks caused by viral strains like H5N1. Such vaccines must be safe, effective, and produced in sufficient quantities to address global demand during a pandemic. Ingredients called adjuvants can potentially make vaccines work better, allowing smaller doses to protect more people.
This clinical trial aims to identify the lowest effective dose of an investigational H5N1 flu vaccine, with one or more adjuvants, to enhance readiness for future influenza outbreaks.
Participants may be eligible if they meet the following:
If eligible, participants will be on study for up to 8 months and will be asked to complete up to 5 clinic visits and 4 phone visits during this period. These visits will be roughly 3 weeks apart for the first 4 visits, with the final visit at the end of study. Visits will need to be done during our clinic business hours of 9am–5pm, Monday–Friday, and may be up to 2.5 hours long.
Clinic visits will include several health assessments, including physical and vital signs measurements, blood tests, medical history collection, pregnancy tests (if applicable) and vaccinations. The doctor and study team will also discuss previous research on the treatment and will outline any possible risks or benefits of participating in the trial.
Each participant will receive 2 vaccinations, with several different combinations and dose levels of investigational influenza vaccines on this study. Participants will not know which group they are assigned to, to prevent bias in the results.
You will be paid up to $1150 for your participation in this study.